GW Pharmaceuticals PLC (NASDAQ: GWPH) recently received a number of ratings updates from brokerages and research firms:

  • 10/6/2017 – GW Pharmaceuticals PLC had its “neutral” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The).
  • 10/2/2017 – GW Pharmaceuticals PLC was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 10/2/2017 – GW Pharmaceuticals PLC had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $165.00 price target on the stock.
  • 10/2/2017 – GW Pharmaceuticals PLC had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $153.00 price target on the stock, down previously from $160.00.
  • 10/2/2017 – GW Pharmaceuticals PLC had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $208.00 price target on the stock.
  • 9/1/2017 – GW Pharmaceuticals PLC was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/16/2017 – GW Pharmaceuticals PLC is now covered by analysts at Evercore ISI. They set an “outperform” rating and a $154.00 price target on the stock.
  • 8/10/2017 – GW Pharmaceuticals PLC was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 8/10/2017 – GW Pharmaceuticals PLC had its “outperform” rating reaffirmed by analysts at Leerink Swann. They now have a $160.00 price target on the stock, down previously from $162.00.
  • 8/8/2017 – GW Pharmaceuticals PLC was given a new $208.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 8/8/2017 – GW Pharmaceuticals PLC was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating. They now have a $61.00 price target on the stock.
  • 8/7/2017 – GW Pharmaceuticals PLC was given a new $135.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.

GW Pharmaceuticals PLC (NASDAQ:GWPH) traded down 3.50% during trading on Friday, hitting $110.53. 176,126 shares of the stock were exchanged. The firm has a 50-day moving average of $105.92 and a 200-day moving average of $108.31. GW Pharmaceuticals PLC has a 52 week low of $92.65 and a 52 week high of $137.88. The stock’s market capitalization is $2.80 billion.

GW Pharmaceuticals PLC (NASDAQ:GWPH) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The business had revenue of $3.14 million during the quarter, compared to analyst estimates of $2.10 million. During the same quarter last year, the company posted ($0.05) earnings per share. Equities research analysts anticipate that GW Pharmaceuticals PLC will post ($5.94) earnings per share for the current fiscal year.

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).

Receive News & Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.